Stelara is an immunosuppressant medication that targets two inflammatory cytokines, IL-12 and IL-23, which are key contributors to chronic inflammation. For Crohn's disease and ulcerative colitis, Stelara is administered every 8 weeks, and for psoriasis, it is given every 12 weeks. Its most frequently reported side effects are an increased susceptibility to infection, as well as nasopharyngitis, headache, and fatigue.
Stelara is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, Crohnâ€™s Disease, and Ulcerative Colitis.
Dupixent is an injectable medication that is typically administered subcutaneously every other week to treat inflammatory conditions, such as asthma and eczema, among others. Injection site reactions and eye conditions are the most frequently reported side effects. The risk of infection is low with Dupixent, unlike other biologics.
Dupixent is FDA approved for the following indications: Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyposis, Eosinophilic Esophagitis, Prurigo Nodularis.